Citi Analysts Affirm Buy Rating on Gilead Sciences (GILD) Stock

On June 2, Citi analysts reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) stock and maintained a $125 price target. The analyst’s bullish stance follows the company presenting data from the ASCENT-04 trial at the American Society of Clinical Oncology (ASCO). The data showed significant progress in the development of Trodelvy as a novel treatment for triple-negative breast cancer (TNBC).

Citi Analysts Affirm Buy Rating and $125 Price Target on Gilead Sciences

A scientist in a laboratory holding a test tube filled with a glowing blue solution, representing the company’s nano-biopharmaceutical research and development.

Clinical trial data showed that when Trodelvy was combined with Keytruda, it significantly reduced the risk of disease progression or death in 35% of patients with PD-L1-positive metastatic TNBC. The combination treatment demonstrated a higher overall response rate of 60% compared to Keytruda and the chemotherapy group.

In addition, the combination improved median progression-free survival by 3.4 months to 11.2 months, which is better than 7.8 months for alternative treatment. Following the positive ASCENT-03 trial, Gilead Science plans to file for full approval, with a decision from the Food and Drug Administration expected in 2026.

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. Its candidate drugs seek to improve the care of patients with life-threatening diseases worldwide.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None.